PLAU Recombinant Monoclonal Antibody

Uniprot Id

P00749

Target Species

Human

Target Name

PLAU

Target Full Name

Urokinase-type plasminogen activator

Target Function

Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.

Target Involvement

Quebec platelet disorder (QPD)

Target Subcellular Location

Secreted.

Target Protein Families

Peptidase S1 family

Target Tissue Specificity

Expressed in the prostate gland and prostate cancers.

Target Research Area

Cardiovascular

Target Synonyms

ATF; ATF uPA; BDPLT5; Plasminogen activator; Plasminogen activator urinary; Plasminogen activator urokinase; PLAU; QPD; u PA; U plasminogen activator; u-PA; U-plasminogen activator; uPA; URK; UROK_HUMAN; Urokinase plasminogen activator; Urokinase type plasminogen activator; Urokinase type plasminogen activator precursor; Urokinase-type plasminogen activator chain B

Target Background

This gene encodes a secreted serine protease that converts plasminogen to plasmin. The encoded preproprotein is proteolytically processed to generate A and B polypeptide chains. These chains associate via a single disulfide bond to form the catalytically inactive high molecular weight urokinase-type plasminogen activator (HMW-uPA). HMW-uPA can be further processed into the catalytically active low molecular weight urokinase-type plasminogen activator (LMW-uPA). This low molecular weight form does not bind to the urokinase-type plasminogen activator receptor. Mutations in this gene may be associated with Quebec platelet disorder and late-onset Alzheimer's disease. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.